Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
NCT06361563 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250
Last updated 2024-04-12
Summary
The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.
Conditions
- Upper Gastrointestinal Cancer
Interventions
- DRUG
-
As per product label
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-05
- Primary Completion
- 2024-01-25
- Completion
- 2024-01-25
- FDA Drug
- Yes
Countries
- Canada
Study Locations
More Related Trials
-
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
NCT06452329 ·Status: COMPLETED
-
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
NCT06504615 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
NCT05334719 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
NCT02872116 ·Status: COMPLETED ·Phase: PHASE3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05111626 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
NCT06235164 ·Status: ACTIVE_NOT_RECRUITING
-
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
NCT04021108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
NCT03662659 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
NCT05153304 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
NCT00061932 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
NCT01585987 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
NCT03784040 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00763646 ·Status: UNKNOWN ·Phase: PHASE2
-
Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ
NCT06739161 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
NCT03615326 ·Status: COMPLETED ·Phase: PHASE3
-
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
NCT00857246 ·Status: COMPLETED ·Phase: PHASE2
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING
-
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
NCT06814548 ·Status: NOT_YET_RECRUITING
-
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
NCT03979131 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
NCT03675737 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02864381 ·Status: COMPLETED ·Phase: PHASE2
-
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
NCT02873520 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
NCT02999295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531 ·Status: RECRUITING ·Phase: PHASE3